PURPOSE: There is variability in the pharmacokinetics (PK) of antibiotics (AB) in critically ill patients. Therapeutic drug monitoring (TDM) could overcome this variability and increase PK target attainment. The objective of this study was to analyse the effect of a dose-adaption strategy based on daily TDM on target attainment. METHODS: This was a prospective, partially blinded, and randomised controlled trial in patients with normal kidney function treated withmeropenem (MEM) or piperacillin/tazobactam (PTZ). The intervention group underwent daily TDM, with dose adjustment when necessary. The predefined PK/pharmacodynamic (PK/PD) target was 100% fT>4MIC [percentage of time during a dosing interval that the free (f) drug concentration exceeded 4 times the MIC]. The control group received conventional treatment. The primary endpoint was the proportion of patients that reached 100% fT>4MIC and 100 % fT>MIC at 72 h. RESULTS:Forty-one patients (median age 56 years) were included in the study. Pneumonia was the primary infectious diagnosis. At baseline, 100% fT>4MIC was achieved in 21% of the PTZ patients and in none of the MEM patients; 100% fT>MIC was achieved in 71% of the PTZ patients and 46 % of the MEM patients. Of the patients in the intervention group, 76 % needed dose adaptation, and five required an additional increase. At 72 h, target attainment rates for 100% fT>4MIC and 100% fT>MIC were higher in the intervention group: 58 vs. 16%, p = 0.007 and 95 vs. 68%, p = 0.045, respectively. CONCLUSIONS: Among critically ill patients with normal kidney function, a strategy of dose adaptation based on daily TDM led to an increase in PK/PD target attainment compared to conventional dosing.
RCT Entities:
PURPOSE: There is variability in the pharmacokinetics (PK) of antibiotics (AB) in critically illpatients. Therapeutic drug monitoring (TDM) could overcome this variability and increase PK target attainment. The objective of this study was to analyse the effect of a dose-adaption strategy based on daily TDM on target attainment. METHODS: This was a prospective, partially blinded, and randomised controlled trial in patients with normal kidney function treated with meropenem (MEM) or piperacillin/tazobactam (PTZ). The intervention group underwent daily TDM, with dose adjustment when necessary. The predefined PK/pharmacodynamic (PK/PD) target was 100% fT>4MIC [percentage of time during a dosing interval that the free (f) drug concentration exceeded 4 times the MIC]. The control group received conventional treatment. The primary endpoint was the proportion of patients that reached 100% fT>4MIC and 100 % fT>MIC at 72 h. RESULTS: Forty-one patients (median age 56 years) were included in the study. Pneumonia was the primary infectious diagnosis. At baseline, 100% fT>4MIC was achieved in 21% of the PTZpatients and in none of the MEM patients; 100% fT>MIC was achieved in 71% of the PTZpatients and 46 % of the MEM patients. Of the patients in the intervention group, 76 % needed dose adaptation, and five required an additional increase. At 72 h, target attainment rates for 100% fT>4MIC and 100% fT>MIC were higher in the intervention group: 58 vs. 16%, p = 0.007 and 95 vs. 68%, p = 0.045, respectively. CONCLUSIONS: Among critically illpatients with normal kidney function, a strategy of dose adaptation based on daily TDM led to an increase in PK/PD target attainment compared to conventional dosing.
Authors: Andrew A Udy; Michael T Putt; Sulochana Shanmugathasan; Jason A Roberts; Jeffrey Lipman Journal: Int J Antimicrob Agents Date: 2010-03-21 Impact factor: 5.283
Authors: Jason A Roberts; Carl M J Kirkpatrick; Michael S Roberts; Andrew J Dalley; Jeffrey Lipman Journal: Int J Antimicrob Agents Date: 2009-12-16 Impact factor: 5.283
Authors: Andrew A Udy; Julie M Varghese; Mahdi Altukroni; Scott Briscoe; Brett C McWhinney; Jacobus P Ungerer; Jeffrey Lipman; Jason A Roberts Journal: Chest Date: 2012-07 Impact factor: 9.410
Authors: R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno Journal: Intensive Care Med Date: 2013-01-30 Impact factor: 17.440
Authors: Fekade Bruck Sime; Michael S Roberts; Sandra L Peake; Jeffrey Lipman; Jason A Roberts Journal: Ann Intensive Care Date: 2012-07-28 Impact factor: 6.925
Authors: Tobias Rachow; Verena Schlüter; Sibylle Bremer-Streck; Udo Lindig; Sebastian Scholl; Peter Schlattmann; Michael Kiehntopf; Andreas Hochhaus; Marie von Lilienfeld-Toal Journal: Infection Date: 2017-05-17 Impact factor: 3.553
Authors: Joan Antoni Schoenenberger-Arnaiz; Faten Ahmad-Diaz; Mar Miralbes-Torner; Ana Aragones-Eroles; Manuel Cano-Marron; Mercedes Palomar-Martinez Journal: Eur J Hosp Pharm Date: 2019-02-27
Authors: A Hecker; B Hecker; K Kipfmüller; J Holler; E Schneck; M Reichert; M A Weigand; W Padberg; M Hecker Journal: Med Klin Intensivmed Notfmed Date: 2014-09 Impact factor: 0.840
Authors: Jan J De Waele; J Lipman; M Akova; M Bassetti; G Dimopoulos; M Kaukonen; D Koulenti; C Martin; P Montravers; J Rello; A Rhodes; A A Udy; T Starr; S C Wallis; J A Roberts Journal: Intensive Care Med Date: 2014-07-23 Impact factor: 17.440